Total Payments
$53,704
2024 Payments
$114.30
Companies
41
Transactions
435
Medicare Patients
5,137
Medicare Billing
$506,263
Payment Breakdown by Category
Research$44,367 (82.6%)
Food & Beverage$8,160 (15.2%)
Travel$1,084 (2.0%)
Education$93.40 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $44,367 | 31 | 82.6% |
| Food and Beverage | $8,160 | 392 | 15.2% |
| Travel and Lodging | $1,084 | 3 | 2.0% |
| Education | $93.40 | 9 | 0.2% |
Payments by Type
Research
$44,367
31 transactions
General
$9,337
404 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $43,975 | 23 | $0 (2023) |
| Biogen, Inc. | $1,884 | 15 | $0 (2021) |
| PFIZER INC. | $1,038 | 42 | $0 (2020) |
| Lilly USA, LLC | $856.06 | 41 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $723.31 | 37 | $0 (2021) |
| GlaxoSmithKline, LLC. | $701.59 | 34 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $605.32 | 26 | $0 (2024) |
| Amgen Inc. | $483.43 | 23 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $363.53 | 21 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $362.79 | 19 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $114.30 | 1 | AstraZeneca Pharmaceuticals LP ($114.30) |
| 2023 | $12,170 | 5 | Eli Lilly and Company ($12,170) |
| 2022 | $5,450 | 6 | Eli Lilly and Company ($5,364) |
| 2021 | $573.28 | 10 | Eli Lilly and Company ($300.00) |
| 2020 | $2,179 | 40 | Eli Lilly and Company ($1,493) |
| 2019 | $2,139 | 100 | Lilly USA, LLC ($391.03) |
| 2018 | $14,799 | 124 | Eli Lilly and Company ($10,873) |
| 2017 | $16,280 | 149 | Eli Lilly and Company ($13,775) |
All Payment Transactions
435 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/28/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $114.30 | General |
| Category: Respiratory | ||||||
| 09/12/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $7,684.00 | Research |
| 04/20/2023 | Eli Lilly and Company | — | — | In-kind items and services | $560.01 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $297.96 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $285.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $3,342.63 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 07/12/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $73.90 | General |
| Category: Diabetes | ||||||
| 06/24/2022 | Lilly USA, LLC | — | Education | In-kind items and services | $11.71 | General |
| 05/09/2022 | Eli Lilly and Company | — | — | In-kind items and services | $4,364.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $428.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $298.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $274.00 | Research |
| Study: RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | ||||||
| 11/18/2021 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $30.40 | General |
| 08/24/2021 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/03/2021 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | Cash or cash equivalent | $27.14 | General |
| Category: NEUROLOGY | ||||||
| 07/20/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $92.59 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/04/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $300.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 04/13/2021 | Lilly USA, LLC | TRULICITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $19.75 | General |
| Category: Diabetes | ||||||
| 03/23/2021 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $20.70 | General |
| 03/15/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $27.78 | General |
| Category: PRIMARY CARE | ||||||
| 01/14/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: PRIMARY CARE | ||||||
| 01/07/2021 | Radius Health, Inc. | Tymlos (Biological) | Food and Beverage | In-kind items and services | $12.88 | General |
| Category: Endocrinology | ||||||
| 12/08/2020 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: Bone Health | ||||||
| 12/01/2020 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: UROLOGY | ||||||
| 11/17/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: RESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3298176 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $19,897 | 2 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $4,364 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $3,343 | 1 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 18-WEEK TRIAL OF INVESTIGATIONAL DULAGLUTIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES ON METFORMIN MONOTHERAPY | Eli Lilly and Company | $2,500 | 1 |
| Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | Biogen, Inc. | $1,806 | 12 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $875.83 | 2 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN | Eli Lilly and Company | $827.96 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $651.50 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $570.50 | 2 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $560.01 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $298.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $297.96 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $285.00 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY | Eli Lilly and Company | $260.85 | 1 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $145.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 891 | 1,239 | $297,923 | $86,870 |
| 2022 | 10 | 985 | 1,290 | $297,829 | $92,270 |
| 2021 | 15 | 1,514 | 2,078 | $494,478 | $158,743 |
| 2020 | 22 | 1,747 | 2,839 | $657,525 | $168,379 |
Total Patients
5,137
Total Services
7,446
Medicare Billing
$506,263
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 234 | 526 | $176,164 | $45,732 | 26.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 155 | 155 | $51,840 | $20,437 | 39.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 101 | 152 | $37,312 | $10,228 | 27.4% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 133 | 133 | $7,972 | $2,516 | 31.6% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 15 | 15 | $6,642 | $2,502 | 37.7% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 132 | 132 | $7,458 | $2,497 | 33.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 12 | 12 | $1,873 | $857.87 | 45.8% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 19 | 20 | $2,344 | $855.00 | 36.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 78 | 82 | $5,210 | $839.22 | 16.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 12 | 12 | $1,108 | $406.08 | 36.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 254 | 378 | $120,960 | $34,632 | 28.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 185 | 185 | $56,610 | $25,091 | 44.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 251 | 405 | $93,150 | $23,640 | 25.4% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 16 | 18 | $7,128 | $2,746 | 38.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 29 | 29 | $1,972 | $1,933 | 98.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 34 | 34 | $2,686 | $1,112 | 41.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 111 | 117 | $7,605 | $1,062 | 14.0% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 46 | 46 | $2,438 | $861.30 | 35.3% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2022 | 42 | 42 | $2,436 | $799.50 | 32.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 17 | 36 | $2,844 | $394.07 | 13.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 334 | 589 | $196,910 | $52,734 | 26.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 372 | 372 | $102,800 | $51,365 | 50.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 329 | 562 | $134,580 | $32,436 | 24.1% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2021 | 24 | 26 | $9,678 | $5,984 | 61.8% |
| 99495 | Transitional care management services, moderately complexity, requiring face-to-face visits within 14 days of discharge | Office | 2021 | 26 | 28 | $8,898 | $4,880 | 54.8% |
About Dr. Michael Mccartney, M.D
Dr. Michael Mccartney, M.D is a Internal Medicine healthcare provider based in Newburyport, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1245211903.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Mccartney, M.D has received a total of $53,704 in payments from pharmaceutical and medical device companies, with $114.30 received in 2024. These payments were reported across 435 transactions from 41 companies. The most common payment nature is "" ($44,367).
As a Medicare-enrolled provider, Mccartney has provided services to 5,137 Medicare beneficiaries, totaling 7,446 services with total Medicare billing of $506,263. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Newburyport, MA
- Active Since 11/09/2005
- Last Updated 01/18/2026
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1245211903
Products in Payments
- TRULICITY (Drug) $2,939
- ELIQUIS (Drug) $588.17
- XARELTO (Drug) $572.80
- CHANTIX (Drug) $571.10
- Aimovig (Biological) $292.23
- Vascepa (Drug) $264.69
- ANORO (Drug) $231.38
- JANUVIA (Drug) $206.96
- TRELEGY ELLIPTA (Drug) $189.59
- LOKELMA (Drug) $179.54
- JARDIANCE (Drug) $174.58
- Ozempic (Drug) $174.41
- TOUJEO (Drug) $174.14
- MYRBETRIQ (Drug) $151.87
- SPIRIVA RESPIMAT (Drug) $150.31
- VIBERZI (Drug) $141.27
- EMGALITY (Drug) $136.66
- INVOKANA (Drug) $132.51
- INCRUSE (Drug) $124.99
- ENTRESTO (Drug) $121.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Newburyport
Houtan Golzari, M.d, M.D
Internal Medicine — Payments: $18,905
Internal Medicine $18,905
Shih-Te Wen, Md, MD
Internal Medicine — Payments: $9,328
Internal Medicine $9,328
Dr. Julie Geary, Md, MD
Internal Medicine — Payments: $6,743
Internal Medicine $6,743
Dr. Anthony Eaton, M.d, M.D
Internal Medicine — Payments: $4,029
Internal Medicine $4,029
Lydia Jeffcoat, Md, MD
Internal Medicine — Payments: $2,569
Internal Medicine $2,569
Saira Naseer, Md, MD
Internal Medicine — Payments: $1,924
Internal Medicine $1,924